◆ 会议时间：2025年9月4-7日
◆ 会议地点：美国 巴尔的摩

◆ 会议简介：

2025年美国心脏协会(AHA)高血压科学会议(HYPERTENSION)将于2025年9月4-7日在美国巴尔的摩举行，会议由美国心脏协会高血压委员会与心血管疾病肾病委员会联合组织，为期三天半的会议，将通过500多场专题报告介绍高血压研究宣的最新进展，与会者将有机会与来自世界各地的跨学科研究人员和临床医生建立联系。本次会议旨在惠及从事高血压研究、心脏病、肾脏病、内分泌及相关学科领域的基础科学家、临床医师和其他医疗专业人员，上届会议有800余名代表出席（未经许可禁止复制摘录转载本站任何内容-领域国际医学会议网）。

美国心脏协会（AHA）成立于1924年，是全球心血管领域学术影响力最大、历史最悠久、最具规模的志愿者组织，致力于心脏病和卒中的预防与治疗。AHA最初由六位心脏病专家创立，现已拥有超过2250万名志愿者和支持者。AHA资助创新研究，争取更强有力的公共卫生政策，并提供关键的工具和信息以拯救生命和改善生活。AHA现包括156个地方办事处和3000多名员工。1997年，美国卒中协会作为一个部门被创建，宗旨是组织与中风相关的活动。

AHA以各种方式提供公共健康教育，以改善所有人的生活。AHA是国家CPR教育培训的领导者，为医护人员提供以科学为基础的治疗指南，以帮助他们为患者提供高质量的护理。AHA教育立法者、政策制定者和公众，提倡改变以保护和改善社会的健康。

AHA Hypertension Scientific Sessions 2025
Sponsored by: Council on Hypertension and Council on Kidney in Cardiovascular Disease

Date: September 4–7, 2025
Location: Marriott Baltimore Waterfront | Baltimore, Maryland, USA

Why You Should Attend Hypertension Scientific Sessions

Connect with cross-disciplinary researchers from around the world and engage with experts at the leading global medical meeting  on hypertension. Discover the latest in hypertension research and foster lasting relationships with researchers  and clinicians across multiple fields and at every stage of their careers.

This meeting features oral and poster presentations, followed by discussions with leading authorities in hypertension as it relates to cardiac and kidney disease, stroke, obesity and genetics. Specially designed sessions benefit trainees and early career investigators, covering topics from applying clinical science to practical advice for primary care providers.

摘要征文投稿：

March 12, 2025: Abstract submission opens

May 21, 2025: Abstract submission closes

点此提交摘要>>>Submit Abstract>>>

Pricing

• AHA Professional Members: $45
• Non-Members: $95

Abstract Submission

• Review Best Practices for Writing Abstracts
• Submit all abstracts in English.
• Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
• Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
• Proofread abstracts carefully to avoid errors before submission. The abstract will be reviewed exactly as submitted.
• An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.
• Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
• Use generic drug names.
• Do not begin sentences with numerals.
• Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
• Do not include references, credits or grant support.
• Do not include the names or personal information of any patient participating in the study or trial.
• The character limit cannot exceed 2,500. Spaces and punctuation count as characters.

Acceptance

• Submitters will be notified of acceptance/non-acceptance status via e-mail by mid-July 2025.
• Abstracts are reviewed in blinded fashion and selected on the basis of scientific merit. The conference Program Committees will determine whether the abstract is to be presented orally or by poster.
• Request oral, poster or moderated poster presentation on the presentation preference tab of the submitter site. Unless you select "poster only" the selection of one of these options will neither prejudice acceptance nor guarantee an oral or moderated poster presentation because abstracts will be arranged to fit into a thematic group for presentation. Although every effort will be made to accommodate your presentation request, there is no guarantee that you will present in the mode of your preference.
• Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.
• Presenting/submitting authors must register and pay associated fees for attendance at the conference.
• Abstracts selected will be published in an online version of Hypertension.
• Accepted abstracts will not have been published (manuscript or abstract) prior to the date of this submission or presented at any national or international meeting prior to September 3, 2025. Abstracts are embargoed for release at date and time of presentation or time of AHA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.
• Submission of an abstract constitutes a commitment by the authors to present if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts.
• Recording Policy:
  • Unauthorized recording of AHA Scientific Sessions, scientific conferences and the ASA International Stroke Conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
  • The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.

Abstract Withdrawal

• There is no guarantee that your abstract will not be published in the final program and the Journal unless request for withdrawal is received in writing via email to specialtyconferences.participant@heart.org by August 5, 2025 at 5:00 p.m. CDT (UTC -5). Please reference "HTN2025."

Abstract Revisions

• Proofread abstracts carefully to avoid errors before submission. No proof pages will be sent to authors.
• Abstracts may not be revised after May 21, 2025 at 6:00 p.m. CDT (UTC -5)

Presentation

• All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
• References to work previously published by other authors must include citations at the bottom of the appropriate slides.
• Unauthorized recording of the conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting AV materials and of poster presentations and supporting poster materials.
• All oral presentations must be in electronic format. Electronic presentations must be submitted 12 business hours in advance of the session start time. Instructions will be provided upon acceptance.

◆ 参会对象：医师、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。